MyFinsight
Home
About
Contact
apls: the income statement
Download
Download image
Syfovre
$150,928K
(-0.68%↓ Y/Y)
Empaveli Pegcetacoplan
$26,827K
(9.00%↑ Y/Y)
Licensing And Other
Revenue
$280,823K
(1286.16%↑ Y/Y)
Product
$177,755K
(0.67%↑ Y/Y)
Revenue
$458,578K
(132.98%↑ Y/Y)
Other
income/(expense), net
$37K
(-47.14%↓ Y/Y)
Interest income
$4,376K
(51.47%↑ Y/Y)
Net operating loss
$223,183K
(572.05%↑ Y/Y)
Total operating
expenses
$235,395K
(-3.57%↓ Y/Y)
Foreign currency
translation
$32K
(-85.59%↓ Y/Y)
Unrealized gain on pension
benefits
-$137K
Net loss before
taxes
$216,317K
(480.48%↑ Y/Y)
Interest expense
$11,279K
(-10.00%↓ Y/Y)
Selling, general and
administrative
$142,678K
(16.96%↑ Y/Y)
Research and development
$68,186K
(-23.01%↓ Y/Y)
Cost of sales
$24,531K
(-26.90%↓ Y/Y)
Total other
comprehensive income
$169K
(-23.87%↓ Y/Y)
Net income/(loss)
$215,715K
(475.52%↑ Y/Y)
Income tax expense
$602K
(1.69%↑ Y/Y)
Comprehensive loss, net of tax
$215,884K
(477.27%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)
APLS_BIG copy-svg
Apellis Pharmaceuticals, Inc. (APLS)